GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » INmune Bio Inc (NAS:INMB) » Definitions » Tangible Book per Share

INMB (INmune Bio) Tangible Book per Share : $1.00 (As of Sep. 2024)


View and export this data going back to 2019. Start your Free Trial

What is INmune Bio Tangible Book per Share?

Tangible book value per share is calculated as the total tangible equity divided by Shares Outstanding (EOP). Total tangible equity is calculated as the Total Stockholders Equity minus Preferred Stock minus Intangible Assets. INmune Bio's tangible book value per share for the quarter that ended in Sep. 2024 was $1.00.

Since intangibles such as goodwill cannot be sold when the company liquidates, tangible book value per share is considered more accurate in reflecting how much shareholders will receive when the company liquidates.


INmune Bio Tangible Book per Share Historical Data

The historical data trend for INmune Bio's Tangible Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

INmune Bio Tangible Book per Share Chart

INmune Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Tangible Book per Share
Get a 7-Day Free Trial 0.66 1.65 3.57 2.43 1.21

INmune Bio Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Tangible Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.57 1.21 0.70 1.04 1.00

Competitive Comparison of INmune Bio's Tangible Book per Share

For the Biotechnology subindustry, INmune Bio's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


INmune Bio's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, INmune Bio's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where INmune Bio's Price-to-Tangible-Book falls into.



INmune Bio Tangible Book per Share Calculation

INmune Bio's Tangible Book Value Per Share for the fiscal year that ended in Dec. 2023 is calculated as

Tangible Book Value per Share=(Total Stockholders Equity-Preferred Stock-Intangible Assets)/Shares Outstanding (EOP)
=(38.139-0-16.514)/17.9508
=1.20

INmune Bio's Tangible Book Value Per Share for the quarter that ended in Sep. 2024 is calculated as

Tangible Book Value per Share=(Total Stockholders Equity-Preferred Stock-Intangible Assets)/Shares Outstanding (EOP)
=(38.675-0-16.514)/22.1724
=1.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total equity is a balance sheet item and equal to total assets less total liabilities of the company. Since intangibles such as goodwill cannot be sold when the company liquidates, tangible book value per share is considered more accurate in reflecting how much shareholders will receive when the company liquidates.


INmune Bio  (NAS:INMB) Tangible Book per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


INmune Bio Tangible Book per Share Related Terms

Thank you for viewing the detailed overview of INmune Bio's Tangible Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


INmune Bio Business Description

Traded in Other Exchanges
N/A
Address
225 NE Mizner Boulevard, Suite 640, Boca Raton, FL, USA, 33432
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.
Executives
David J Moss 10 percent owner, officer: CFO, Treasurer & Secretary C/O PEGASI ENERGY RESOURCES CORPORATION, 218 N. BROADWAY, SUITE 204, TYLER TX 75702
Raymond Joseph Tesi director, 10 percent owner, officer: President & CEO 476 MASSACHUSETTS AVE, UNIT 2, BOSTON MA 02118
Scott Juda director 325 N. LARCHMONT BLVD, SUITE 375, LOS ANGELES CA 90004
Mark William Lowdell 10 percent owner, officer: Chief Scientific Officer THE OAK, WLX ROAD, BEAUMONT X0 CO16 0AT
Timothy J Schroeder director 2690 DEVILS BACKBONE ROAD, CINCINNATI OH 45233
Linda F Powers 10 percent owner 7600 WISCONSIN AVENUE, SUITE 700, BETHESDA MD 20814
James Kelly Ganjei director 10609 RIVER OAKS LANE, POTOMAC MD 20859
Marcia Allen director P.O. BOX 399, 2600 W. HOMESTEAD CIRCLE, WILSON WY 83014
Edgardo Jr Baracchini director C/O METABASIS THERAPEUTICS, 9390 TOWNE CENTRE DRIVE, BLDG. 300, SAN DIEGO CA 92121
Xencor Inc 10 percent owner 465 N. HALSTEAD ST., SUITE 200, PASADENA CA 91107
David Edmund Szymkowski director 241 WEST PALM AVENUE, MONROVIA CA 91016